FIRST AMENDMENT TO THE NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • June 16th, 2021 • MorphoSys AG • Pharmaceutical preparations
This First Amendment (“Amendment”) to the Non-Disclosure Agreement, dated November 5, 2020 (“Agreement”) is effective as of the date of the last signature below (the “Amendment Effective Date”), and is made and entered into between:
Re: Non-Disclosure AgreementNon-Disclosure Agreement • June 16th, 2021 • MorphoSys AG • Pharmaceutical preparations • Delaware
In connection with the consideration of a possible negotiated transaction (a “Possible Transaction”) involving MorphoSys AG, a German stock corporation (Aktiengesellschaft) (collectively, with its subsidiaries, the “Recipient”), and Constellation Pharmaceuticals, Inc., a Delaware corporation (collectively, with its subsidiaries, the “Company”); each of Recipient and the Company is referred to as a “Party” and together as the “Parties”), the Company is prepared to make available to Recipient certain information concerning the Company, including its business, financial condition, operations, strategy, assets and liabilities.
MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENTMutual Confidential Disclosure Agreement • June 16th, 2021 • MorphoSys AG • Pharmaceutical preparations • New York
This Mutual Confidential Disclosure Agreement (the “Agreement”), dated as of the last signature hereof (the “Effective Date”) is by and between Constellation Pharmaceuticals Inc., a Delaware corporation, having an address at 215 First Street, Suite 200, Cambridge, Massachusetts 02142 (“Constellation”) and MorphoSys AG having an address at Semmelweisstr. 7, 82152 Planegg, Germany.
